Citi analyst Daniel Grosslight lowered the firm’s price target on Privia Health (PRVA) to $32 from $34 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health price target raised to $33 from $31 at Truist
- Privia Health price target raised to $35 from $34 at Canaccord
- Privia Health price target raised to $32 from $30 at Jefferies
- Privia Health reports Q4 adjusted EPS 25c, consensus 19c
- Privia Health sees 2026 revenue $2.35B-$2.45B, consensus $2.32B